权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Implementing tobacco use treatment in HIV clinics in Viet Nam

在越南艾滋病毒诊所实施烟草使用治疗

基本信息

批准号：
10854280
负责人：
Nam Truong Nguyen
金额：
$ 18.35万
依托单位：
NEW YORK UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-01 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10854280
关键词：
Abstinence Attitude Behavioral Belief Cancer Control Cancer Etiology Cancer Patient Cessation of life Clinic Communities Consultations Development Dimensions Economics Emotions Evaluation Face Foundations Funding Future Generations Goals Guilt HIV Health Personnel Health care facility High-Risk Cancer Income Individual Influentials Intervention Interview Investigation Knowledge Life Malignant Neoplasms Malignant neoplasm of lung Measures Mental disorders Outcome Patients Persons Policies Populations at Risk Procedures Process Productivity Property Provider Psychometrics Psychosocial Factor Research Rights Risk Role Self Disclosure Shame Shapes Smoking Social Values Stereotyping Stigmatization Testing Tobacco Use Cessation Tobacco use Tobacco-Related Carcinoma Validation Validity and Reliability Vietnam Vietnamese arm cancer care cancer prevention cancer risk cognitive testing compare effectiveness design discount effectiveness-implementation RCT experience health administration high risk insight interest low and middle-income countries mortality peer prevent professional atmosphere psychosocial response screening social social exclusion social stigma

项目摘要

ABSTRACT This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-23-036. Cancer stigma among healthcare providers (HCPs) can impede and decrease the effective delivery and quality of cancer care, particularly in low-and-middle income country (LMIC) settings. Accurate, culturally-adapted assessments of cancer stigma in LMICs among HCP’s, who have been understudied to date, can thus inform efforts to mitigate this key barrier and contribute to clinicians’ efforts to effectively control and prevent cancer in these settings. The supplemental study, which is integrated into a three-arm tobacco cessation implementation-effectiveness randomized control trial among PLWH in Viet Nam, will develop a multi-component cancer stigma scale for clinicians (MCCSS-C), with an additional focus on lung cancer, for use among clinicians who treat patients who are at risk for cancer, and examine how cancer stigma is correlated with psychosocial and behavioral factors. First, a qualitative investigation will be conducted to understand how cancer stigma—and specifically lung cancer stigma—manifests among clinicians who treat patients who are at risk for cancer to inform the development of a cancer stigma measure for HCPs in Viet Nam. In this investigation, HCP’s attitudes and beliefs towards cancer patients (as well as those of their peer co-workers’) will be used to inductively identify new clinician domains of stigma towards people with cancer, with the main objective of exploring how the different components of HCP cancer stigma (i.e., perceived community stigma, negative attitudes and emotions, enacted co-worker stigma, and health facility policies/work environment) are perceived among Vietnamese HCP’s. Following selection of the final items to comprise each dimension-specific stigma subscale, the MCCSS-C will undergo initial psychometric evaluation. The revised MCCSS-C (both the “general cancer stigma” and “lung cancer stigma” versions) will be administered to 30 new HCPs to assess both its initial psychometric properties and the relationships between different cancer stigma dimensions and select psychosocial factors. Little is known about how cancer stigma may manifest in HCPs whose patients are at higher risk of developing cancer, specifically in LMICs, and key insights into this harmful social dynamic along with culturally-salient expressions of stigma will be elucidated in the process of developing our measure. An evaluation of cancer stigma among clinicians who treat people with HIV will act as a key step towards developing a future scale that will generalize to all clinicians in Vietnam and have applicability to clinicians in LMICs overall.

摘要